This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Leading Patient Organizations Establish Partnership To Improve The Lives Of Tens Of Millions Of Rare Disease Patients In Japan And The U.S.

Japan Patients Association (JPA) and National Organization for Rare Disorders (NORD) to Collaborate Toward New Treatments and Improved Policies

WASHINGTON, Jan. 29, 2013 /PRNewswire-USNewswire/ -- The Japan Patients Association (JPA) and the National Organization for Rare Disorders (NORD)—the primary organizations representing patients and families affected by rare diseases in Japan and the U.S.—announced today that they have signed a memorandum of understanding to collaborate and improve the lives of their constituents. 

(Photo: http://photos.prnewswire.com/prnh/20130129/DC49655)

(Logo: http://photos.prnewswire.com/prnh/20110719/DC37656LOGO-b)

The partnership uniting the JPA and NORD was formally established in Washington, D.C. by Tateo Ito, president of the JPA, and Peter L. Saltonstall, president and CEO of NORD. 

"Our organizations have a shared mission and goals," Ito said.  "We would like to make use of our valuable knowledge and experiences for the mutual benefit of patients in both countries."

"Global collaboration will drive progress toward new treatments, improved public policies and better lives for people with rare diseases," Saltonstall said.  "We look forward to working together on behalf of the rare disease communities in Japan and the U.S., reinforcing our commitment to partnerships that advance patients' needs."

Per the memorandum of understanding, "it is becoming increasingly evident that addressing challenges related to rare and intractable diseases often requires international collaboration … patients, their families and patient organizations affected by rare and intractable diseases often share similar challenges even though they may live in different parts of the world."

A declaration of shared commitment to improving the lives of rare disease patients and families, the partnership specifies that the two organizations will share information about current advocacy initiatives and seek ways to increase understanding and communication between rare disease patients and patient organizations in Japan and the U.S.

About the Japan Patients Association

The JPA is a non-profit umbrella organization established in 2005.  It focuses on rare and intractable diseases and has a membership of approximately 300,000 from 72 organizations, including individual patient groups and regional centers.  JPA provides patient/family services and advocacy on public policies.  It also collaborates with other organizations in Japan and organizes patients' forums.

For more information about JPA, please visit www.nanbyo.jp.

About NORD

Celebrating its 30 th anniversary year, the National Organization for Rare Disorders (NORD) is a unique federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them.  A nonprofit organization, NORD represents the 30 million Americans with rare diseases and is committed to the identification, treatment and cure of rare disorders through patient assistance, education, advocacy and research.  NORD represents approximately 200 member organizations.

In addition to this new partnership with JPA, NORD also has a strategic alliance with EURORDIS (Rare Diseases Europe) to connect rare disease patients in the U.S. and Europe through global online communities ( www.RareConnect.org) and other initiatives.

For more information about NORD, please visit www.rarediseases.org.   

SOURCE National Organization for Rare Disorders (NORD)

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,431.98 +7.13 0.04%
S&P 500 1,863.41 +1.10 0.06%
NASDAQ 4,095.1280 +8.9030 0.22%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs